Asthma Diagnosis via Airway Epithelial Cell Cycle Synchronization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments primarily focus on inflammation, but they fail to effectively address the complex interactions among multiple cell types in the lung, including non-inflammatory resident cells, which are crucial for asthma pathogenesis, leading to incomplete symptom relief and long-term pathological remodeling.
Innovation Solution
A model placing airway epithelium at the center of a network of interacting inflammatory mediators, using cell cycle synchrony as a diagnostic and therapeutic target, where compositions like glucocorticoids, statins, and antineoplastic agents pause mitosis briefly to synchronize cell cycles, improving asthma treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current asthma treatments focus on inflammation, then inflammatory symptoms are reduced, but non-inflammatory resident cells are not effectively addressed leading to incomplete symptom relief and long-term pathological remodeling
Solution Approach 1:
The patent applies universality by developing a diagnostic model that evaluates multiple cell types (inflammatory cells, non-inflammatory resident cells, and airway epithelium) simultaneously rather than focusing solely on inflammatory cells. This multi-functional approach allows the treatment strategy to address both inflammatory and non-inflammatory components of asthma pathogenesis, thereby improving overall treatment efficacy and coverage across different cell populations.
Solution Approach 2:
The patent segments the asthma diagnostic and treatment approach into distinct cellular components: inflammatory cells, non-inflammatory resident cells, and airway epithelium. By measuring cell cycle synchrony specifically in airway epithelium and evaluating the functional status of different cell types separately, the model enables targeted interventions that address specific cellular deficiencies while maintaining comprehensive disease management.
2Object-generated harmful factors
If glucocorticoids are used to reduce inflammation, then inflammatory pathways are suppressed, but cell cycle dysregulation in airway epithelium persists
Solution Approach 1:
The patent implements feedback by using the diagnostic model to measure cell cycle synchrony in airway epithelium and the functional status of different cell types, then using this information to guide and adjust treatment strategies. This feedback loop allows clinicians to monitor whether treatments are effectively addressing both inflammatory suppression and cell cycle regulation, enabling real-time optimization of therapy to achieve both goals simultaneously.
Solution Approach 2:
The patent applies parameter changes by shifting the diagnostic focus from solely measuring inflammatory markers to also measuring cell cycle synchrony parameters in airway epithelium. This change in measurement parameters reveals previously undetected aspects of asthma pathogenesis and allows for treatment adjustments that address cell cycle dysregulation alongside inflammatory suppression.
3Adaptability or versatility
If high doses of drugs are administered to address complex cell interactions, then treatment coverage is improved, but side effects increase
Solution Approach 1:
The patent applies local quality by identifying specific cellular deficiencies through the diagnostic model (such as asynchrony in airway epithelium cell cycles or functional deficits in particular cell types) and targeting treatments to address those specific local issues rather than applying blanket high-dose therapy. This localized approach improves treatment coverage of specific pathological mechanisms while minimizing unnecessary drug exposure and associated side effects.
Data Source
AI summary
The present invention relates to asthma. Particularly, the present invention relates to clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development for the treatment of asthma. The present invention relates to a new paradigm in diagnosing, screening, and treating asthma by affecting airway epithelial synchronization.